Taltz (ixekizumab) / Eli Lilly, Japan Tobacco - LARVOL DELTA

Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab (PubMed, Rev Alerg Mex) - "We report a patient with HLAB27+ spondyloarthritis treated with ixekizumab who developed a systemic IgE-mediated reaction. A successful and easy to perform subcutaneous desensitization protocol is described."

Journal • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Pulmonary Disease • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis (EAACI 2025) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Immunology • Psoriasis

Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis. (PubMed, Postgrad Med) - "Guselkumab and Secukinumab demonstrated the highest drug survival rates, whereas Ixekizumab had the lowest. Early improvements in PASI and DLQI scores were strong predictors of drug survival. Personalized treatment approaches are crucial, given the varied effectiveness, safety profiles, and drug survival among biologic therapies."

Journal • Real-world evidence • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis • Respiratory Diseases • IL12A • IL17A • IL23A

BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis. (PubMed, Rheumatol Adv Pract) - "More than 70% of biologic-naïve r-axSpA patients who achieved an ASAS40 response, also attained low disease activity or inactive disease as measured by the BASDAI or ASDAS. Findings may help clinicians translate results from clinical trials into daily practice."

Journal • Retrospective data • Ankylosing Spondylitis • Back Pain • Fatigue • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Pain • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Chinese herbal medicine (Guben Qushi Huayu formula) combined with Ixekizumab in reducing psoriasis vulgaris relapse: Protocol for a mixed-methods research study. (PubMed, Front Pharmacol) - P=N/A | "Moreover, it is our intention to conduct a larger MMR trial to further strengthen the clinical evidence and broaden the application of Ixekizumab in combination with GQHF. https://www.chictr.org.cn/index.html, identifier ChiCTR2100054950."

Journal • Dermatology • Immunology • Psoriasis

Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (ISPOR 2025) - "Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private"

Dermatology • Immunology • Inflammation • Psoriasis

Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice. (PubMed, Psoriasis (Auckl)) - "Patient characteristics, including nail psoriasis and treatment history, influenced drug survival differently for each treatment. These findings underscore the importance of personalized treatment strategies in managing psoriasis."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A

Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation. (PubMed, J Pharmacol Exp Ther) - "Antibodies targeting IL17A (such as secukinumab and ixekizumab) have been approved to treat psoriasis, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis and are under further investigation as therapies in inflammatory disorders such as hidradenitis suppurativa and giant cell arteritis. SIGNIFICANCE STATEMENT: This study found that orally active small molecule antagonists of the proinflammatory cytokine IL17A that preferentially bind the IL17A/A form produced equivalent efficacy to monoclonal antibodies that can neutralize both IL17A/A and IL17A/F. This indicates that the IL17A/A homodimer is the dominant isoform driving inflammation in diseases such as psoriasis and that oral inhibitors targeting IL17A/A may be useful next-generation IL17 therapeutics."

Journal • Preclinical • Ankylosing Spondylitis • Dermatitis • Dermatology • Giant Cell Arteritis • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

The Efficacy, Safety and Longevity of Biologic Treatments in Pediatric and Adult Psoriasis Patients: A Comparative Multi-Center, Real-Life Study. (PubMed, Ann Dermatol) - "Although responses to ETA and UST were numerically better among children, the difference was insignificant. The DS rates in each group were comparable, and no specific safety signals, limiting the long-term use of these agents, were detected in the pediatric group."

Journal • Dermatology • Immunology • Pediatrics • Psoriasis

Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Treated with Biologics: A nationwide study using target trial emulation framework. (PubMed, Br J Dermatol) - "The findings suggested ustekinumab and guselkumab may be associated with a reduced risk of HZ and PHN, compared to TST. This study could have significance for real-world practice."

Journal • Dermatology • Herpes Zoster • Immunology • Inflammatory Arthritis • Neuralgia • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Varicella Zoster • IL12A • IL17A • IL23A

Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. (PubMed, Curr Issues Mol Biol) - "A significant decrease in SUA levels was noticed, especially in patients treated with IL-17 inhibitors. Further studies should identify which bDMARD is the most potent in the lowering of SUA levels. bDMARDs were efficient in PsA disease activity."

Journal • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Emerging Manifestations of IL-17 Immunomodulation in the Gastrointestinal Tract (USCAP 2025) - "Biologics targeting the IL-17 signaling pathway (ixekizumab, secukinumab) have been approved to treat conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis...All patients with clinical follow-up data (n=4) required IBD therapeutic regimens for symptom improvement/resolution in addition to IL-17 inhibitor cessation; these regimens included combinations of steroids, infliximab, and ustekinumab... Patients on IL-17 inhibitors with new-onset colitis have a clinical and histologic spectrum that overlaps with IBD, primary immunodeficiencies, and other immunomodulatory therapies. Pathologists should consider the possibility of IL-17 associated colitis in patients with autoimmune diseases. Future studies and expanded cohorts should determine whether IL-17 inhibitors unmask IBD in predisposed individuals, cause de novo IBD, or represent a self-limited medication-associated reaction."

Immunomodulating • Ankylosing Spondylitis • Dermatology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Primary Immunodeficiency • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

TOGETHER-PsA: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (clinicaltrials.gov) - P3 | N=250 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative persistence and effectiveness of ixekizumab versus other b/tsDMARD classes in real-world PsA treatment: 12-month results from the PRO-SPIRIT study (EULAR 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology

ADALIMUMAB vs. IXEKIZUMAB EFFECTIVENESS IN PATIENTS WITH PSORIATIC ARTHRITIS: A REAL-WORLD MULTICENTER STUDY WITH MATCH-ADJUSTED COMPARISONS (EULAR 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

What is the profile of axial spondyloarthritis patients treated with ixekizumab and its effectiveness in clinical practice Results from the ESPADA study (EULAR 2025) - No abstract available

Clinical • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis

Efficacy of ixekizumab in radiographic axial spondyloarthritis patients with normal and elevated CRP: A pooled analysis of phase III clinical trials (EULAR 2025) - No abstract available

P3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis

Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial (EULAR 2025) - No abstract available

Clinical • P3 data • Inflammatory Arthritis • Seronegative Spondyloarthropathies

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Hypopigmented mycosis fungoides-like eruption following ixekizumab treatment. (PubMed, JAAD Case Rep) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Psoriasis • T Cell Non-Hodgkin Lymphoma • Vitiligo

A real-world study of ixekizumab use patterns, switching and efficacy in patients with plaque psoriasis. (PubMed, Arch Dermatol Res) - "Ixekizumab can extend the dosing interval in patients who respond well. Switching biologic therapy between ixekizumab and secukinumab and adalimumab may be considered, as this switching strategy is also used in difficult-to-treat areas."

Journal • Real-world evidence • Retrospective data • Dermatology • Immunology • Psoriasis

Intra-Class Interleukin-(IL)-17 Blocker Switching: Ixekizumab as a Solution for Secukinumab Non-responders in Secondary Biologic Failure in Psoriasis. (PubMed, Cureus) - "This approach is particularly relevant in regions with high latent tuberculosis prevalence where TNF-alpha inhibitors are less viable. Further research is needed to confirm these results in larger cohorts."

Journal • Dermatology • Immunology • Infectious Disease • Psoriasis • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IL17A

Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post-marketing surveillance. (PubMed, J Dermatol) - "The mean Psoriasis Area and Severity Index score and body surface area percentage significantly decreased from baseline to week 52 for all psoriasis subtypes and by Q2/Q2 and Q2/Q4 ixekizumab doses (p < 0.01 or p < 0.001). Overall, the safety and effectiveness of ixekizumab in real-world settings in Japan were similar to those reported in clinical trials."

Journal • P4 data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Pustular Psoriasis • Rheumatology • Seronegative Spondyloarthropathies

“Extension of indication to include treatment of juvenile idiopathic arthritis for TALTZ, based on week 16 results from study I1F-MC-RHCG…as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted. Furthermore, the PI is in line with the latest QRD template version 10.4” (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC)-Draft agenda for the meeting on 10 - 13 Mar 2025: “For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP”

PRAC • Idiopathic Arthritis • Inflammation